LanzaTech Global, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LanzaTech Global, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.85M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $49.59M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $62.63M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $37.34M | Feb 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.95M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($137.73M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($134.10M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($76.36M) | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | $46.7K | Mar 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.16M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($108.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($106.38M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($75.60M) | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | ($1.39M) | Mar 25, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $77.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $68.14M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $53.19M | Feb 29, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.05M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $49.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $50.44M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $26.80M | Feb 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($64.85M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($89.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($97.30M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($84.70M) | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | ($510.0K) | Mar 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.31M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.55M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $10.74M | Feb 29, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $174.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $241.62M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $176.86M | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | $150.87M | Mar 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $161.24M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $127.15M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $124.95M | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | $11.61M | Mar 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.45M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $114.47M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($428.72M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($354.92M) | Feb 29, 2024 |
| FY2021 | Jan 27, 2021 | $0 | Mar 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.02B) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($969.60M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($831.87M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($456.25M) | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | ($10.74M) | Mar 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.16M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $43.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $75.59M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $83.05M | Feb 29, 2024 |
| FY2021 | Dec 31, 2021 | $343.4K | Mar 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (69) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Feb 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (69) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Feb 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 1.95M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 196.64M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 10.42M | Feb 29, 2024 |